LOS ANGELES, CA - May 19, 2026 (NEWMEDIAWIRE) - Most people are aware that cardiovascular disease (“CVD”) is the leading cause of death in the United States; what they might not know is that an estimated 80% of those cases are considered preventable through earlier detection and proactive management of key risk factors. This highlights the urgent need for more effective tools that can identify risk earlier and guide personalized intervention strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is rising to the challenge by developing a suite of clinical, population health and biopharma solutions designed to leverage artificial intelligence (“AI”), epigenetics and genetics to improve cardiovascular disease prevention, detection and management.

• Research supports the urgent need for more effective tools to identify the risk of cardiovascular disease earlier and guide personalized intervention strategies.
• Cardio Diagnostics’ solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care.
• This emphasis on prevention aligns with growing recognition that earlier intervention can significantly improve long-term outcomes.

The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing. Cardio Diagnostics currently offers two clinical solutions, Epi+Gen CHD(TM) and PrecisionCHD(TM), as well as a…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Cardio Diagnostics Holdings (CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention.